Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.

Carlos King-Ho WongKristy Tsz Kwan LauXi XiongIvan Chi Ho AuFrancisco Tsz Tsun LaiEric Yuk Fai WanCeline Sze Ling ChuiXue LiEsther Wai Yin ChanLe GaoFranco Wing Tak ChengSydney Chi-Wai TangIan Chi Kei Ck Wong
Published in: PLoS medicine (2022)
In this study, we observed that the incidences of AESIs (cumulative incidence rate of 0.06%-0.09%) and mortality following the first and second doses of CoronaVac and BNT162b2 vaccination were very low. The safety profiles of the vaccines were generally comparable, except for a significantly higher incidence rate of Bell palsy, but lower incidence rates of anaphylaxis and sleeping disturbance or disorder, following first dose CoronaVac versus BNT162b2 vaccination. Our results could help inform the choice of inactivated COVID-19 vaccines, mainly administered in low- and middle-income countries with large populations, in comparison to the safety of mRNA vaccines. Long-term surveillance on the safety profile of COVID-19 vaccines should continue.